END BRAIN CANCER

Everything we do is directed towards our ultimate mission, which is to End Brain Cancer within our lifetimes. We are unique in the one-on-one personalized support we offer to brain tumor patients and their families... This month's CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative (EBCI), www.EndBrainCancer.org, and through our patient advocacy and disease education partnership with CURE, focuses on turning Glioblastoma Multiforme (GBM) from a deadly disease into a chronic managed disease through turning GBM patients into cancer survivors through metabolic targeting of GBM through Aminolevulinic Acid (ALA) Sonodynamic Therapy (SDT). ALA and SDT is created through the union of two FDA-approved technologies: ALA tumor targeting and focused ultrasound (FUS). ALA SDT uses am MRI-guided focused ultrasound (MRGFUS) device together with a drug, ALA, to provide a cancer-specific therapeutic effect. To learn more about this approach, please visit: https://sonalasense.com/for-..

Primary location: Redmond United States